FDA approves Merck’s RSV shot for infants, ramping up competition with Sanofi and AstraZeneca
Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.
You are not logged in so some information on this page has been withheld. To see more, please log in.
Beyfortus
since
auto-detected in 13 stories
8 days ago
page 1 of 1